Another proposed possibility is the measurement of the “intent to attend” the next study visit and to use this as a covariate to decrease the attrition bias.94 In addition, identifying patients who are not likely to continue in the study or who find participation burdensome prior to their dropping
out can help http://www.selleckchem.com/products/AZD2281(Olaparib).html research personnel to proactively address barriers to trial completion. Finally, allowing for in-person, two-way video or telephone assessments in the patient’s home should also be considered to reduce Inhibitors,research,lifescience,medical the amount of missing data. Trial Implementation and conduct One of the most Enzastaurin supplier neglected areas of clinical trials is trial management and oversight. As signal detection has become increasingly difficult and sample sizes have increased, the conduct and quality control of large-scale RCTs Inhibitors,research,lifescience,medical has become increasingly complex and difficult.65 Subsequently, many companies have outsourced this important aspect of trial implementation and performance. As a result, there is the danger of a loss of control and diffusion or narrowing of responsibility, in that clinical Inhibitors,research,lifescience,medical research organizations are mostly in charge of assuring that increasingly tight time lines are kept and quota are met. The enormous time pressures can lead to a problematic disconnect between the desired quantity
and the desired quality of enrolled patients and assessments. Moreover, increasing regulatory requirements can also lead to an overburdening of sites and investigators who are not part of professional clinical trials sites and who might drop out of multisite RCTs, thereby Inhibitors,research,lifescience,medical narrowing the settings in which patients are studied. Furthermore, the focus on assuring adherence to formal requirements, which has appropriately attracted scrutiny and attention, should not distract from assessing the quality of the trial conduct that is not equivalent to following checklists and increasingly complex documentation. To Inhibitors,research,lifescience,medical overcome some of these problems, recent concern has focused on finding ways to encourage trial management organizations to broaden their responsibility beyond considerations
of documentation and fulfilling quota. GSK-3 Rather, methods need to be considered that provide incentives to these organizations to assure adherence to appropriate standards of patient selection and high quality assessments, follow-up, protocol adherence, and retention. However, a high placebo response or lack of separation of the investigational drug or standard comparator from placebo cannot automatically or solely be used as a quality indicator. Moreover, quality adherence should also be measurable and achievable during the conduct of the trial and not only after its conclusion. Therefore, the field needs to develop standards against which sites and clinical trial management organizations can be assessed and which can provide clear guidance to all parties involved in the conduct of the trial.